A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Inclusion Criteria for treatment period: Participants eligible for inclusion in this study must meet all of the following criteria: * Male or female patients ≥ 18 years of age. * Participants with CML-CP within 3 months of diagnosis. * Diagnosis of CML-CP (ELN 2020 criteria) with cytogenetic confirmation of Philadelphia chromosome Documented chronic phase CML will meet all the below criteria (Hochhaus et al 2020): * \< 15% blasts in peripheral blood and bone marrow, * \< 30% blasts plus promyelocytes in peripheral blood and bone marrow, * \< 20% basophils in the peripheral blood, * Platelet count ≥ 100 x 10\^9/L (≥ 100,000/mm\^3), * No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate end organ function as defined by: * Total bilirubin \< 3 x ULN; patients with Gilbert's syndrome may only be included if total bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN * Creatinine clearance (CrCl) ≥ 30 mL/min as calculated using Cockcroft-Gault formula, * Serum lipase ≤ 1.5 x ULN. For serum lipase \> ULN - ≤ 1.5 x ULN, value must be considered not clinically significant and not associated with risk factors for acute pancreatitis \- Participants must have the following laboratory values within normal limits or corrected to within normal limits with supplements prior to randomization: * Potassium (potassium increase of up to 6.0 mmol/L is acceptabl…